Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

ESMO open·2026

Same author

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.

ESMO open·2025

Same author

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Ten years survival results of randomized study comparing weekly <i>vs</i>. triweekly cisplatin with concurrent radiation in locally advanced carcinoma cervix.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology·2023

Same journal

Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.

Gut·2026

Same journal

Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment.

Gut·2026

Same journal

USP20 promotes CD8<sup>+</sup> T cell exhaustion and impairs KRAS<sup>G12D</sup> inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.

Gut·2026

Same journal

CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease.

Gut·2026

Same journal

<i>Helicobacter pylori</i> infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials.

Gut·2026

Same journal

Correction: Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.

Gut·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 11, 2026

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Endoscopic sclerotherapy using absolute alcohol.

S K Sarin, G K Sachdeva, R Nanda

|February 1, 1985

Summary

This summary is machine-generated.

Absolute alcohol effectively treats esophageal varices through endoscopic sclerotherapy, achieving high eradication rates and controlling acute bleeding. This safe and economical sclerosant is recommended for variceal bleeding management.

More Related Videos

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

Related Experiment Videos

Last Updated: May 11, 2026

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

Area of Science:

Gastroenterology
Hepatology
Endoscopic procedures

Background:

Portal hypertension frequently leads to esophageal varices, a major cause of life-threatening bleeding.
Endoscopic sclerotherapy is a common treatment, but sclerosant efficacy and safety remain areas of investigation.

Purpose of the Study:

To evaluate the efficacy and safety of absolute alcohol as a sclerosant for endoscopic sclerotherapy in patients with esophageal varices.

Main Methods:

Forty-three patients with portal hypertension and variceal bleeding underwent endoscopic sclerotherapy using absolute alcohol and an indigenously designed injector.
Treatment involved a weekly sclerotherapy schedule, with outcomes assessed based on bleeding control, variceal size reduction, and eradication rates.

Main Results:

Acute bleeding was controlled in all 11 actively bleeding patients.
Significant reduction in variceal size was observed, with 80% variceal eradication in patients completing at least four sessions.
Mean treatment duration was approximately 9 weeks, with no new varices appearing during follow-up.

Conclusions:

Absolute alcohol is an effective, safe, economical, and readily available sclerosant for endoscopic sclerotherapy.
Endoscopic sclerotherapy with absolute alcohol is recommended as a first-line treatment for acute variceal bleeding, with a weekly schedule promoting early eradication.